EVGN Logo

Evogene Ltd (EVGN) Stock Forecast & Price Prediction

Live EVGN Stock Price & Analysis

Home โ€บ Stocks โ€บ Israel | NASDAQ | Healthcare | Biotechnology

$1.47

+0.00 (0.00%)

12 Month Price Forecast For EVGN

$1.47
Current Price
$9.73M
Market Cap
2 Ratings
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to EVGN Price Forecasts

+665.3%
To High Target of $11.25
+452.7%
To Median Target of $8.13
+240.1%
To Low Target of $5.00

EVGN Price Momentum

-5.2%
1 Week Change
-20.5%
1 Month Change
-80.7%
1 Year Change
-21.4%
Year-to-Date Change
-85.9%
From 52W High of $10.40
+22.5%
From 52W Low of $1.20

๐Ÿค” Considering Evogene (EVGN)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 5, 2025 11:50 PM UTC

EVGN Analyst Ratings & Price Targets

Based on our analysis of 5 Wall Street analysts, EVGN has a consensus that is bullish. The median price target is $8.13, with forecasts ranging from $5.00 to $11.25. Currently, there are 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.

With EVGN currently trading at $1.47, the median price forecast suggests a 452.7% upside. The most optimistic forecast comes from at , projecting a 665.3% upside, while at provides the most conservative target, suggesting a 240.1% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

EVGN Analyst Consensus

2
Buy
0
Hold
0
Sell

EVGN Price Target Range

Low
$5.00
Average
$8.13
High
$11.25
Current: $1.47

Latest EVGN Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for EVGN.

Date Firm Analyst Rating Change Price Target
Aug 23, 2024 Lake Street Ben Klieve Buy Maintains $12.00
Oct 2, 2023 Alliance Global Partners Ben Haynor Buy Initiates $1.85
Aug 18, 2023 Lake Street Ben Klieve Buy Maintains $3.00
Jul 21, 2023 Roth MKM Buy Maintains $0.00
May 2, 2023 Lake Street Ben Klieve Buy Initiates $2.00
Sep 12, 2022 Aegis Capital Nathan Weinstein Buy Maintains $8.00
Sep 2, 2022 Roth MKM Buy Maintains $0.00
Oct 8, 2021 Roth Capital Brian Wright Buy Initiates $7.00
Jul 29, 2021 Aegis Capital Buy Initiates $0.00
Dec 1, 2020 Cantor Fitzgerald Overweight Initiates $0.00
Nov 12, 2014 Credit Suisse Outperform Maintains $22.00
Dec 17, 2013 Deutsche Bank Buy Initiates $0.00
Dec 16, 2013 Credit Suisse Outperform Initiates $0.00

Stocks Similar to Evogene Ltd

The following stocks are similar to Evogene based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Evogene Ltd (EVGN) Financial Data

Evogene Ltd has a market capitalization of $9.73M with a P/E ratio of 0.3x. The company generates $9.45M in trailing twelve-month revenue with a -210.3% profit margin.

Revenue growth is +39.8% quarter-over-quarter, while maintaining an operating margin of -667.1% and return on equity of -82.4%.

Valuation Metrics

Market Cap $9.73M
Enterprise Value $5.18M
P/E Ratio 0.3x
PEG Ratio -0.4x
Price/Sales 1.0x

Growth & Margins

Revenue Growth (YoY) +39.8%
Gross Margin +39.8%
Operating Margin -667.1%
Net Margin -210.3%
EPS Growth -52.3%

Financial Health

Cash/Price Ratio +279.0%
Current Ratio 1.6x
Debt/Equity 4.1x
ROE -82.4%
ROA -28.5%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Evogene Ltd logo

Evogene Ltd (EVGN) Company Overview

About Evogene Ltd

What They Do

Operates as a computational biology company.

Business Model

The company utilizes its Computational Predictive Biology (CPB) platform to drive product discovery and development across three main segments: Agriculture, Human Health, and Industrial Applications. It generates revenue by developing innovative seed traits, ag-chemical products, and therapeutics, as well as providing medical cannabis products.

Additional Information

Founded in 1999 and headquartered in Rehovot, Israel, Evogene Ltd. operates internationally in markets such as the United States, Brazil, and more. The company's focus on enhancing plant performance and developing human microbiome-based therapeutics positions it well within the growing life-science industries.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

142

CEO

Mr. Ofer Haviv CPA

Country

Israel

IPO Year

2010

Evogene Ltd (EVGN) Latest News & Analysis

EVGN stock latest news image
Quick Summary

Evogene Ltd. (NASDAQ:EVGN) will hold its Q3 2024 earnings conference call on November 21, 2024, at 9:00 AM ET, featuring key company executives.

Why It Matters

Evogene's Q3 earnings call indicates upcoming financial performance insights, impacting stock valuation and investor sentiment based on growth or challenges revealed.

Source: Seeking Alpha
Market Sentiment: Neutral
EVGN stock latest news image
Quick Summary

For the first nine months of 2024, revenues were $6.9M, up from $5.1M in 2023. Q3 2024 revenues were $1.8M, down from $3.8M in Q3 2023.

Why It Matters

The revenue growth in the first nine months signals positive performance, but the significant drop in Q3 raises concerns about sustainability and potential market challenges.

Source: PRNewsWire
Market Sentiment: Neutral
EVGN stock latest news image
Quick Summary

Lavie Bio Ltd. reported strong results from its third consecutive year of field trials in Europe, highlighting its progress in ag-biologicals.

Why It Matters

Strong trial results for LAV321 enhance Lavie Bio's market position and growth potential, potentially boosting investor confidence and stock performance in the ag-biologicals sector.

Source: PRNewsWire
Market Sentiment: Neutral
EVGN stock latest news image
Quick Summary

Lavie Bio plans to start sales of its Yalosยฎ soybean product in the spring of 2025, as announced on November 12, 2024.

Why It Matters

Yalosยฎ sales starting in spring 2025 could boost Lavie Bio's revenues and market position, influencing stock performance and investor sentiment in the ag-biological sector.

Source: PRNewsWire
Market Sentiment: Neutral
EVGN stock latest news image
Quick Summary

Evogene Ltd. will release its Q3 2024 financial results on November 21, 2024, at 9:00 AM ET, and will hold a conference call to discuss the results.

Why It Matters

The upcoming earnings call could reveal key financial insights and strategic developments for Evogene Ltd., influencing investor sentiment and stock performance.

Source: PRNewsWire
Market Sentiment: Neutral
EVGN stock latest news image
Quick Summary

Casterra Ag Ltd. delivered over 100 tons of castor oil to a customer in Africa, enhancing its role in bio-based products and biofuel production.

Why It Matters

The shipment indicates strong demand for Casterra's products, signaling potential revenue growth and market expansion, which could positively impact stock performance and investor sentiment.

Source: PRNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About EVGN Stock

What is Evogene Ltd's (EVGN) stock forecast for 2025?

Based on our analysis of 5 Wall Street analysts, Evogene Ltd (EVGN) has a median price target of $8.13. The highest price target is $11.25 and the lowest is $5.00.

Is EVGN stock a good investment in 2025?

According to current analyst ratings, EVGN has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.47. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for EVGN stock?

Wall Street analysts predict EVGN stock could reach $8.13 in the next 12 months. This represents a 452.7% increase from the current price of $1.47. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Evogene Ltd's business model?

The company utilizes its Computational Predictive Biology (CPB) platform to drive product discovery and development across three main segments: Agriculture, Human Health, and Industrial Applications. It generates revenue by developing innovative seed traits, ag-chemical products, and therapeutics, as well as providing medical cannabis products.

What is the highest forecasted price for EVGN Evogene Ltd?

The highest price target for EVGN is $11.25 from at , which represents a 665.3% increase from the current price of $1.47.

What is the lowest forecasted price for EVGN Evogene Ltd?

The lowest price target for EVGN is $5.00 from at , which represents a 240.1% increase from the current price of $1.47.

What is the overall EVGN consensus from analysts for Evogene Ltd?

The overall analyst consensus for EVGN is bullish. Out of 5 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.13.

How accurate are EVGN stock price projections?

Stock price projections, including those for Evogene Ltd, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.